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Abstract
Background: Ligand-driven modulation of the mitochondrial translocator protein 18 kDa (TSPO) was recently described
to dampen the neuroinflammatory response of microglia in a retinal light damage model resulting in protective effects
on photoreceptors. We characterized the effects of the TSPO ligand XBD173 in the postischemic retina focusing
on changes in the response pattern of the major glial cell types of the retina—microglia and Müller cells.
Methods: Retinal ischemia was induced by increasing the intraocular pressure for 60 min followed by reperfusion
of the tissue in mice. On retinal cell types enriched via immunomagnetic separation expression analysis of TSPO,
its ligand diazepam-binding inhibitor (DBI) and markers of glial activation were performed at transcript and protein level
using RNA sequencing, qRT-PCR, lipid chromatography-mass spectrometry, and immunofluorescent labeling. Data on
cell morphology and numbers were assessed in retinal slice and flatmount preparations. The retinal functional integrity
was determined by electroretinogram recordings.
Results: We demonstrate that TSPO is expressed by Müller cells, microglia, vascular cells, retinal pigment epithelium
(RPE) of the healthy and postischemic retina, but only at low levels in retinal neurons. While an alleviated
neurodegeneration upon XBD173 treatment was found in postischemic retinae as compared to vehicle controls,
this neuroprotective effect of XBD173 is mediated putatively by its action on retinal glia. After transient ischemia, TSPO
as a marker of activation was upregulated to similar levels in microglia as compared to their counterparts in healthy
retinae irrespective of the treatment regimen. However, less microglia were found in XBD173-treated postischemic
retinae at 3 days post-surgery (dps) which displayed a more ramified morphology than in retinae of vehicle-treated
mice indicating a dampened microglia activation. Müller cells, the major retinal macroglia, show upregulation
of the typical gliosis marker GFAP. Importantly, glutamine synthetase was more stably expressed in Müller glia
of XBD173-treated postischemic retinae and homeostatic functions such as cellular volume regulation typically
diminished in gliotic Müller cells remained functional.
Conclusions: In sum, our data imply that beneficial effects of XBD173 treatment on the postischemic survival
of inner retinal neurons were primarily mediated by stabilizing neurosupportive functions of glial cells.
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Background
Müller cells maintain the retinal homeostasis fulfilling a
number of functions including ion and cell volume regu-
lation, neurotransmitter recycling, and expression of
neuroprotective factors [1–3]. They are highly respon-
sive to pathological triggers, a reaction termed Müller
cell gliosis. Its relevance under pathological conditions is
still under debate. Some authors postulate gliosis being
primarily detrimental for the long-term survival and/or re-
generation of neuronal structures, while others point out
neuroprotective aspects [4, 5]. Recently, we demonstrated
that this Müller cell gliosis includes changes in their elec-
trophysiological properties (e.g., downregulation of Kir4.1
potassium channels) and a concomitant loss of their abi-
lity of volume regulation resulting in a constrained ion
and volume homeostasis of the Müller cells with likely
consequences on other retinal structures [2, 6]. We also
showed that a modified gliotic activation leading to a
stable Kir4.1 channel function in reactive Müller cells is
beneficial for the survival of inner retinal neurons in the
postischemic retina [6].
Translocator protein 18 kDa (TSPO) is an integral
membrane protein of the outer mitochondrial mem-
brane, although a localization at the plasma membrane
and in or at the nucleus has also been suggested [7]. In
the central nervous system (CNS), its expression is pri-
marily confined to ependymal cells, microglia, and astro-
cytes [8–10]. TSPO functions in cell physiology are
diverse but still controversially discussed [11–13]. There is
evidence for a role in neurosteroidogenesis as it binds
cholesterol, the input substrate for the latter, and shuttles
it to the inner mitochondrial membrane where neuro-
steroid biosynthesis is initiated [7, 11]. Additionally,
anti-inflammatory effects of TSPO activity [14] and a re-
duced respiratory activity in neuroblastoma cells upon
treatment with the TSPO ligand PK 11195 [15] have been
implicated. In line with these findings, TSPO deficiency
leads to a reduced respiratory activity in microglia [16].
Even though the physiological function of TSPO awaits
unequivocal proof of existing concepts, a body of literature
also described neuroprotective effects of TSPO agonists in
disease models of the central [17–19] and peripheral [20]
nervous system. Consequently, pharmacological modula-
tion of TSPO is a promising tool of neuroprotection.
TSPO expression in the retina was primarily assigned
to reactive microglia [21, 22]. Moreover, treatment with
the TSPO agonists enhanced allopregnanolone produc-
tion with concomitantly improved retinal cell survival in
an ex vivo model of high-pressure glaucoma [23] and
better photoreceptor survival as well as a dampened
microglial response in a model of retinal light damage
[24]. The endogenous ligand, diazepam binding inhibitor
(DBI), was reported to be exclusively expressed by
Müller cells [22]. Accordingly, it was speculated about a
close interplay of Müller cells and microglia coordinat-
ing the retinal immune response via TSPO signaling.
Given the preexisting data demonstrating (i) an upre-
gulation of TSPO in microglia [21, 22] and reactive as-
trocytes in the brain [9], (ii) a protective effect of agonistic
TSPO ligands in damaged peripheral and central nervous
system, and (iii) findings that it modulates the glial re-
sponse pattern in the context of retinal disease [24], we




All substances were purchased from Sigma-Aldrich
(Taufkirchen, Germany) unless stated otherwise. Papain
was obtained from Roche (Mannheim, Germany).
Chloromethyl-tetramethyl-rosamine (Mitotracker Orange)
was purchased from Molecular Probes (Life Technologies,
Carlsbad, CA, USA). For immunofluorescence staining,
the following primary antibodies were used: mouse
anti-glial fibrillary acidic protein (GFAP; 1:200; G-A-5
clone, Sigma), goat anti-calretinin (1:500, Swant, Marly,
Switzerland), rabbit-anti-Aif1 (1:500, Wako Chemicals),
mouse anti-glutamine synthetase (1:1000, Merck Milli-
pore, Darmstadt, Germany), rabbit anti-TSPO (1:100,
Abcam, Cambridge, UK), and rabbit anti-DBI (1:200,
Sigma). As secondary antibodies, we used Cy5-conjugated
donkey anti-goat, Cy3-conjugated donkey anti-rabbit,
Cy2-conjugated donkey anti-mouse, Cy3-conjugated goat
anti-rabbit, and Cy2-conjugated goat anti-mouse. All
secondary antibodies were obtained from Dianova
(Hamburg, Germany) and applied at 1:200 dilution.
Animals
All experiments were done in accordance with the
European Community Council Directive 2010/63/EU
and the ARVO Statement for the Use of Animals in
Ophthalmic and Vision Research and were approved by
the local authorities (55.2 DMS-2532-2-182). Mice were
maintained with free access to water and food in an
air-conditioned room on a 12-h light-dark cycle. For all
experiments, C57Bl/6J mice at the age of 2–4 months
were used.
Retinal ischemia
Transient retinal ischemia was always induced in one
eye by the high intraocular pressure (HIOP) method.
Anesthesia was induced with ketamine (100mg/kg body
weight, intraperitoneal (ip); Ratiopharm, Ulm, Germany),
xylazine (5mg/kg, ip; Bayer Vital, Leverkusen, Germany),
and atropine sulfate (100mg/kg, ip; Braun, Melsungen,
Germany). The anterior chamber of the test eye was
cannulated from the pars plana with a 30-gauge infusion
needle, connected to a saline bottle. The intraocular
Mages et al. Journal of Neuroinflammation           (2019) 16:43 Page 2 of 16
pressure was increased to 160mmHg for 60min by ele-
vating the bottle. After removing the needle, the animals
survived for a defined time span as indicated for the
respective experiments and, subsequently, were sacrificed
with carbon dioxide. The contralateral eye was not cannu-
lated and served as internal control. Animals of the
XBD173 treatment group received two intraperitoneal
injections per day (10mg/kg body weight XBD173
(Tocris, Wiesbaden-Nordenstadt, Germany) dissolved in
DMSO (anhydrous, ≥ 99.9% pure, Sigma Aldrich)) starting
1 day before the surgery and at the day of the surgery.
Thereafter, they received a daily injection of 10mg/kg
body weight until the animal was sacrificed for analysis.
The vehicle group was injected the same volume of
DMSO as if the respective amount of XBD173 would have
been administered according to the same time schedule as
the XBD173 group.
Histological and immunohistochemical staining
Enucleated eyes were immersion-fixed (4% parafor-
maldehyde for 2 h), washed with phosphate-buffered
saline (PBS), cryoprotected in sucrose, embedded in
Tissue-Tek® O.C.T. compound (Sakura Finetek, Staufen,
Germany), and cut in 20 μm sections using a cryostat.
Retinal sections were permeabilized (0.3% Triton X-100
plus 1.0% DMSO in PBS) and blocked (5% normal goat
serum with 0.3% Triton X-100 and 1.0% DMSO in PBS)
for 2 h at room temperature. Primary antibodies were in-
cubated overnight at 4 °C. The sections were washed (1%
bovine serum albumin in PBS) and incubated with sec-
ondary antibodies (2 h at room temperature). Cell nuclei
were labeled with DAPI (1:1000; Life Technologies). Ret-
inal whole mounts were labeled using a similar protocol,
except that tissue was permeabilized by higher concentra-
tions of Triton X-100 and DMSO (1% Triton X-100 plus
3% DMSO in PBS), and secondary antibodies were also
incubated at 4 °C overnight. Control experiments without
primary antibodies showed no unspecific labeling except
for the goat-anti-mouse secondary antibody which labeled
the blood vessels (not shown). Images were taken with
custom-made VisiScope CSU-X1 confocal system (Visi-
tron Systems, Puchheim, Germany) equipped with a
high-resolution sCMOS camera (PCO AG, Kehlheim,
Germany). Cell nuclei and calretinin-positive neuronal
cells were counted in three retinal layers in 150-μm-wide
areas of the central retina close to the optic nerve head
(optical slice thickness, 1.5 μm) using ImageJ [25].
Magnetic-activated cell sorting (MACS) of retinal cells
Müller cells were enriched as described previously [26].
Briefly, retinae were digested with papain (0.2 mg/ml;
Roche Molecular Biochemicals) for 30 min at 37 °C in
the dark in Ca2+- and Mg2+-free extracellular solution
(140 mM NaCl, 3 mM KCl, 10 mM HEPES, 11 mM glu-
cose, pH 7.4). Thereafter, the tissue was incubated with
DNase I (200 U/ml) and triturated in extracellular solu-
tion containing (mM) 135 NaCl, 3 KCl, 2 CaCl2, 1
MgCl2, 1 Na2HPO4, 10 HEPES, and 11 glucose adjusted
to pH 7.4 with Tris. After centrifugation, cells were re-
suspended and incubated in an extracellular solution
containing biotinylated hamster anti-CD29 (clone Ha2/5,
0.1 mg/ml, BD Biosciences, Heidelberg, Germany) for
15 min at 4 °C. Cells were washed in extracellular solu-
tion, spun down, resuspended in the presence of
anti-biotin MicroBeads (1:5; Miltenyi Biotec, Bergisch
Gladbach, Germany), and incubated for 10 min at 4 °C.
After washing, CD29+ Müller cells were separated
using large cell (LS) columns according to the manufac-
turer’s instructions (Miltenyi Biotec). To purify micro-
glial and vascular cells in addition to Müller cells, the
retinal cell suspension was subsequently incubated with
CD11b− and CD31 microbeads (Miltenyi Biotec) and
the respective binding cells were depleted from the re-
tinal suspension using LS columns prior to Müller cell en-
richment. The cell population depleted from CD11b+,
CD31+, and CD29+ cells was considered as the neuronal
fraction. However, it needs to be stated that this cell popu-
lation, we termed “neuronal fraction” in the further
manuscript, was negatively selected and thus a minor
contamination with other so far unspecified cell types
cannot be completely excluded. Given the cellular
composition of the retina, the vast majority of these
cells however are rod photoreceptors making up about
80% of all retinal cells [27]. As described previously
[26], the purity of the CD29+ Müller cell fraction was
checked via immunolabeling of the cell suspension for
the Müller cell marker glutamine synthetase and a
DAPI counterstain to assess total cell numbers. Müller
cell purity was above 80% with photoreceptors consti-
tuting the main contaminating cell population. Suc-
cessfully enrichment of the other cell population was
validated by expression analysis of marker genes at the
protein (mass spectrometry) and transcript (RNA se-
quencing) level (see Fig. 1).
In sum, none of the cell populations is 100% pure,
but needs to be understood as a cell population
enriched for a specific cell type like CD31+ vascular
cells, CD11b+ microglia and/or invading macrophages
(a better discrimination by additional surface markers
would lead sample sizes not suitable for the methods
used for expression analysis), and CD29+ Müller glia
(and few astrocytes). Accordingly, we always inves-
tigated the expression of respective genes of interest
in all cell populations to get a better overview in
which cell types changes in expression levels of genes
of interest occur in response to the ischemic insult
(see Fig. 2).
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RNA sequencing
After the immunoseparation of retinal cell types, total
RNA was isolated from cell pellets using the Pure-
Link® RNA Micro Scale Kit (Thermo Fisher Scientific,
Schwerte, Germany). Validation of RNA integrity and
quantification was performed using the Agilent RNA
6000 Pico chip analysis according to the manufac-
turer’s instructions (Agilent Technologies, Waldbronn,
Germany). Enrichment of mRNA and library prepa-
ration (Nextera XT, Clontech), library quantification
Fig. 1 TSPO signaling in different retinal subpopulations. a To assess which retinal cell types are directly involved in TSPO-mediated signaling in
the healthy murine retina, we enriched microglia, vascular cells, Müller glia, and retinal neurons via immunomagnetic separation. Subsequently,
cells were submitted to mass spectrometric analysis to determine protein expression levels. Bar diagrams depict the protein abundance in the
respective cell populations for the following cell type-specific marker genes: integrin alpha-M (ITGAM); allograft inflammatory factor 1 (AIF1)—microglia;
platelet endothelial cell adhesion molecule (PECAM1); intercellular adhesion molecule 2 (ICAM2)—vascular cells; retinaldehyde-binding protein 1
(RLBP1); glutamine synthetase (GLUL)—Müller glia; vesicular glutamate transporter 1 (SLC17A7); rhodopsin (RHO)—retinal neurons including
photoreceptors. b Transcript and protein expression of TSPO and its endogenous ligand diazepam binding inhibitor (DBI) in the four
investigated retinal cell populations. a, b Values are given as mean ± SEM (n = 4–9 biological replicates). c TSPO—glutamine synthetase
(GLUL) colabeling in retinal slice (left) and flatmount (right) preparations at indicated focus planes. Vessels (yellow arrowheads) and Müller
glia (blue arrowheads) are positive for punctuate TSPO labeling indicative of a primarily mitochondrial localization of TSPO. Note the high
expression level of TSPO in the retinal pigment epithelium (RPE). GCL, ganglion cell layer; IPL, inner plexiform layer; INL, inner nuclear
layer; OPL, outer plexiform layer; ONL, outer nuclear layer. Scale bars, 50 μm
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(KAPA Library Quantification Kit Illumina, Kapa Bio-
systems, Inc., Woburn, MA, USA), and sequencing on
an Illumina platform (NextSeq 500 High Output Kit v2;
150 cycles) were performed at the service facility KFB
Center of Excellence for Fluorescent Bioanalytics (Re-
gensburg, Germany; www.kfb-regensburg.de). After de-
multiplexing, a total of at least 20 million reads per sample
was reached. Quality control of the reads and quantifica-
tion of transcript abundance were performed with the
Tuxedo suit, as described elsewhere [Pubmed ID26239128
and doi: https://doi.org/10.1007/978-1-4939-8669-9_2].
Briefly, adapter sequences were removed with cutadapt
[DOI:https://doi.org/10.14806/ej.17.1.200], and several
quality control measures were queried with fastqc. No
major problems with the sequencing data were de-
tected. Next, the trimmed reads were aligned to the
reference genome/transcriptome (mm10) with HISAT2
[https://doi.org/10.1038/nmeth.3317], and transcript
Fig. 2 TSPO expression in the postischemic retina. a Retinal flatmounts labeled for TSPO focused on the ganglion cell and outer plexiform layer
(GCL, OPL) at 3 and 14 dps. While in control retinae primarily endothelial cells and Müller cells appear to be positively labeled, TSPO-positive
macrophages/microglia (arrowheads) show up in the postischemic retina irrespective of the treatment regimen. Scale bars, 20 μm. b Quantitative
real-time PCR (qPCR) performed on retinal cell populations enriched via magnetic activated cell sorting. Bars represent mean values ± SEM (n
= 3–6 mice of each treatment group and time point). */°/•P < 0.05. The color of the circle indicates the treatment group
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abundance was estimated with stringtie, expressed as
fragments per 1000 bp of transcript per million reads
(FPKM).
qRT-PCR
Like for RNAseq, total RNA was isolated from enriched
cell populations using the PureLink® RNA Micro Scale
Kit (Thermo Fisher Scientific, Schwerte, Germany). A
DNase digestion step was included to remove genomic
DNA (Roche). First-strand cDNAs from 10 to 50 ng of
total RNA were synthesized using the RevertAid H
Minus First-Strand cDNA Synthesis Kit (Fermentas by
Thermo Fisher Scientific, Schwerte, Germany). Primers
were designed using the Universal ProbeLibrary Assay
Design Center (Roche). Transcript levels of candidate
genes were measured by qRT-PCR using cDNA with
the TaqMan hPSC Scorecard™ Panel (384 well, ViiA7,
Life Technologies, Darmstadt, Germany) according to
the company’s guidelines.
LC-MS/MS mass spectrometric analysis
LC-MS/MS analysis was performed as described pre-
viously [28, 29] on an Q Exactive HF mass spectrometer
(Thermo Fisher Scientific Inc., Waltham, MA, USA)
coupled to an Ultimate 3000 RSLC nano-HPLC (Dionex,
Sunnyvale, CA). Approximately 0.5 μg per sample were
automatically loaded onto a nano-trap column (300 μm
inner diameter × 5 mm, packed with Acclaim Pep-
Map100 C18. 5 μm, 100 Å; LC Packings, Sunnyvale, CA)
before separation by reversed phase chromatography
(HSS-T3M-class column, 25 cm, Waters) in a 80-min
non-linear gradient from 3 to 40% acetonitrile (ACN) in
0.1% formic acid (FA) at a flow rate of 250 nl/min.
Eluted peptides were analysed by the Q-Exactive HF
mass spectrometer equipped with a nano-flex ionization
source. Full-scan MS spectra (from m/z 300 to 1500)
and MSMS fragment spectra were acquired in the Orbi-
trap with a resolution of 60,000 or 15,000, respectively,
with maximum injection times of 50 ms each. The up to
ten most intense ions were selected for HCD fragmenta-
tion depending on signal intensity (TOP10 method).
Target peptides already selected for MS/MS were dy-
namically excluded for 30 s. Label-free analyses (includ-
ing database search and protein identification was
performed as follows. Spectra were analyzed using Pro-
genesis QI software for proteomics (Version 3.0,
Non-linear Dynamics, Waters, Newcastle upon Tyne,
UK) for label-free quantification as previously de-
scribed [26]. All features were exported as Mascot
generic file (mgf ) and used for peptide identification
with Mascot (version 2.4) in the UniProtKB/Swis-
s-Prot taxonomy mouse database (release 2017.02,
16,871 sequences). Search parameters used were 10
ppm peptide mass tolerance and 20 mmu fragment
mass tolerance, one missed cleavage allowed, carba-
midomethylation was set as fixed modification, me-
thionine oxidation and asparagine or glutamine
deamidation were allowed as variable modifications. A
Mascot-integrated decoy database search calculated an
average false discovery of < 1%.
Müller cell soma size and volume regulation
Volume changes of Müller cell somata were measured
as described previously [30]. Briefly, retinal slices were
loaded with the vital dye Mitotracker Orange (10 μM,
excitation 543 nm, emission 560-nm-long-pass filter;
Life Technologies), which is preferentially taken up by
Müller cells [31]. Slices were exposed to a hypotonic
solution (60% of control osmolarity using distilled
water for dilution) for 4 min. Somata of labeled Müller
cells were imaged using confocal microscopy (cus-
tom-made VisiScope CSU-X1 confocal system equipped
with a high-resolution sCMOS camera; Visitron Systems,
Puchheim, Germany), and their cross-sectional areas were
measured (ImageJ).
Full-field electroretinography
Mice were dark adapted for at least 12 h before recor-
dings and anesthetized by subcutaneous injection of
ketamine (65 mg/kg) and xylazine (13 mg/kg). The pupils
were dilated with tropicamide eyedrops (Mydriaticum
Stulln; Pharma Stulln). Silver needle electrodes served as
a reference (forehead) and ground (tail) and gold wire
ring electrodes as active electrodes. Corneregel (Bausch
& Lomb, Berlin, Germany) was applied to keep the eye
hydrated and to maintain good electrical contact. ERGs
were recorded using a Ganzfeld bowl (Ganzfeld QC450
SCX, Roland Consult, Brandenburg, Germany) and an
amplifier with a recording unit (RETI-Port, Roland Con-
sult). ERGs were recorded from both eyes simulta-
neously, band-pass filtered (1 to 300 Hz), and averaged.
Single flash scotopic (dark adapted) responses to a series
of ten LED-flash intensities ranging from − 3.5 to
1.0 log cd.s/m2 with an interstimulus interval of 2 up to
20 s for the highest intensity were recorded. Responses
were quantified based on mean waveform peak ampli-
tude and implicit time. All analysis and plotting were
carried out with R 3.2.1 (The R Foundation for Statistical
Computing) and ggplot2 2.1.0.
Statistics
All data are expressed as mean ± standard error (SEM)
unless stated otherwise. Statistical analyses were per-
formed using Prism (GraphPad Software, San Diego,
CA, USA). In most of the experiments, in the present
study, results from four to six biological replicates were
collected to keep to the rules of the three Rs for the sake
of animal welfare. Since this low number of input values
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does not allow an appropriate estimation about a normal
Gaussian distribution, significance levels were determined
by the non-parametric Mann-Whitney U test unless stated
otherwise.
Results
TSPO upregulation in distinct retinal cell types of the
ischemic retina
Performing cell type-specific expression analysis at tran-
script and protein level from microglia, vascular cells,
Müller glia, and retinal neurons (Fig. 1a), we found that
TSPO is expressed at the highest levels in Müller glia
and vascular cells in the healthy neuroretina (Fig. 1b).
Immunolabeling for TSPO confirmed these findings and
additionally underpinned its robust expression also in
the retinal pigment epithelium (RPE) underlying the
retina (Fig. 1c). Only little TSPO expression was de-
tected in microglia, particularly if considering protein
levels (Fig. 1b).
Next, we investigated the TSPO expression in retinae
that had been subjected to transient ischemia (60 min)
and subsequent reperfusion. The XBD173 group re-
ceived intraperitoneal injections starting 1 day before is-
chemia was induced, while the DMSO group only was
injected with the solvent. We found a strong increase of
immunoreactivity for TSPO in activated microglia after
ischemia as it has been described after light damage [21]
(Fig. 2a). There were no obvious changes in the labeling
pattern of the other TSPO expressing cell populations
(Figs. 2a and 4a). Performing the cell type-specific
expression profiling for TSPO mRNA expression in the
postischemic retina at different time points after surgery,
we found a significant upregulation in microglia of
XBD173- and vehicle-treated individuals at 3 days post-
surgery (dps) and a subsequent drop of expression to
almost baseline levels at 7 dps (Fig. 2b). No significant
difference in TSPO regulation in microglia was found
between both treatment groups with a tendency of even
stronger TSPO upregulation in microglia of XBD173-
treated retinae. TSPO transcript expression was slightly
but significantly enhanced in Müller glia of XBD173-
treated mice already in the healthy control eye and was
then significantly upregulated at 7 dps (Fig. 2b), thus few
days later as observed in microglia.
XBD173 modifies the microglial response after transient
ischemia
We went on to investigate other features of microglia
activation, since major effects of TSPO agonists on
microglia had been described earlier [21, 24]. We found
a significantly changed microglial morphology as early as
3 dps. Most cells presented with an amoeboid-shaped
phenotype having almost completely retracted their pro-
cesses (Fig. 3a). This morphological change is reflected
by a smaller area occupied by processes of a single mi-
croglia. Of note, microglia maintained a slightly more
ramified morphology in postischemic retinae of XBD173-
compared to DMSO-treated mice (Fig. 3b) at 3 dps. Next,
we asked where microglia accumulated in the postis-
chemic tissue and found considerable differences. At
3 dps, twice as many microglia were present in the plexi-
form layers of postischemic retinae of vehicle controls as
compared to the XBD173 group (Fig. 3c). At 14 dps, the
differential microglia distribution was no longer notice-
able, and the microglial response was declining (e.g., less
cells, more ramified morphology) in the outer plexiform
layer, while the cells were still highly activated in the more
severely affected inner retina (Fig. 3b, c).
Since expression data are normalized to housekeeper
expression, higher RNA detection rates represent en-
hanced levels of respective gene expression and are not
due to increased microglia numbers that occur concomi-
tantly. In line with that, a stronger labeling intensity per
microglial cell can be appreciated in the anti-AIF1
immunolabeling (Fig. 3a). Interestingly, significantly
lower expression levels of Aif1 and Itgam in retinal
microglia were observed in cells from XBD173-treated
postischemic eyes at 3 dps—the time point of peaking
microglia activation (Fig. 3d). Next, we investigated the
effect of XBD173 treatment on the microglial differenti-
ation into the M1 (pro-inflammatory) or M2 (regenera-
tive) phenotype. Regarding M1 markers, we found a
significantly less pronounced rise of F4/80 expression in
microglia of XBD173-treated mice at 3 dps, while no
change in Tnf transcript levels was observed (Fig. 3e).
Moreover, we found that Arg1 was upregulated from
7 dps on in microglia irrespective of XBD173 treatment
(Fig. 3f ).
In summary, we found a dampened but robust micro-
glial response to acute ischemia-induced retinal dege-
neration also in animals subjected to XBD173 treatment.
Altered Müller cell gliosis after XBD173 treatment
Given that Müller cells express the highest protein levels
of TSPO in the healthy retina (apart from the also strong
expression in the underlying RPE), we tested for specific
effects of XBD173 treatment on them. Labeling for
TSPO revealed no major alteration of its expression level
in Müller glia 7 dps compared to the control eyes at pro-
tein level even though slightly higher mRNA expression
had been detected (Figs. 2b and 4a). Immunoreactivity
for the endogenous TSPO ligand DBI colocalized with
the Müller cell marker glutamine synthetase but pro-
duced a rather diffuse labeling of spot-like structures
across all retinal layers (Fig. 4a). No major changes in
the DBI labeling intensity were observed in the postis-
chemic retinae of both treatment groups 7 dps. Glial
fibrillary acidic protein (GFAP)—a common marker of
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Müller cell gliosis—was upregulated in Müller cells of
XBD173-treated retinae to a similar degree as in DMSO
controls as early as 3 dps and stayed at a constantly high
level until 14 dps as determined by immunolabeling
(Fig. 4a) and quantitative PCR (Fig. 4b). Even though no
obvious difference had been detected via immunolabe-
ling, we also found a significant rise in Müller cell DBI
expression at transcript level around 7 dps (Fig. 4c). Of
note, DBI expression was not influenced by XBD173
treatment (Fig. 4c). Finally, we observed that glutamine
synthetase, a key enzyme in the glutamate-glutamine
cycle, was downregulated at 3 and 7 dps in Müller cells
of vehicle controls in line with the findings from earlier
studies [32] (Fig. 4d). At 14 dps, expression levels
Fig. 3 Characterization of the microglial activation pattern in the postischemic retina upon XBD173 treatment. a Aif1 labeling of retinal
flatmounts delineating microglia in the inner plexiform layer representative of cells quantified in the inner retina (INR) and the outer plexiform
layer (OPL) at 3 and 14 dps. Scale bars, 20 μm. b Determination of the area occupied by processes of individual microglia as a measure for their
activation status. c Microglia were quantified (n = 4 for each condition) in the OPL and INR (e.g., ganglion cell and inner plexiform layer).
d Expression levels of Aif1 and Itgam were detected via qPCR. Note that especially 3 days (3) after ischemia, both Aif1 and Itgam
expression was the highest in microglia of untreated mice indicative of a stronger microglial activation at this time point Control, c. e Markers
for pro-inflammatory M1 microglia were investigated via qPCR in MACS-sorted cells. TNFα (Tnf) expression was similar in both treatment groups
except for microglia 14 days (14) post-surgery. In contrast, less F4/80 was expressed in microglia of XBD173-treated mice. f Arginase 1 (Arg1) is a marker
for anti-inflammatory, protective M2 microglia. Enhanced expression of Arg1 transcripts may indicate improved neuroprotection in the stressed
postischemic retina. b–f Bars represent mean values ± SEM (n = 3–6 mice of each treatment group and time point). */°/•P < 0.05; °°P < 0.01; •••P < 0.001.
The color of the circle indicates the treatment group
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Fig. 4 Müller glial reactivity in the postischemic retina. a Top, retinal slices from control and 7 days post-surgery (dps) eyes were labeled for TSPO
and counterstained for the Müller cell marker glutamine synthetase (GLUL). Colabeling of TSPO and GLUL in Müller cell processes and end feet
are pointed out by blue arrowheads. Middle, immunolabeling for the microglia marker AIF1 and glial fibrillary acidic protein (GFAP), a marker for
Müller cell gliosis. Bottom, immunoreactivity for DBI partially colocalizes to that of GLUL. White arrowheads point at putative microglia. Expression
of Gfap (b), Dbi (c), and Glul (d) was tested by qPCR from MACS-enriched Müller cells of control (c), 3, 7, and 14 dps. b–d Bars represent mean
values ± SEM (n = 3–6 mice of each treatment group and time point). */°/•P < 0.05; °°P < 0.01; °°°/•••P < 0.001. The color of the circle indicates the
treatment group. e Retinal flatmounts labeled for GLUL and focused on the ganglion cell layer (GCL) demonstrating reduced expression of GLUL
at 3 dps which are more pronounced in postischemic retina of vehicle controls. a, e Scale bars, 50 μm
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partially recovered. Interestingly, the reduction of glu-
tamine synthetase expression in XBD173-treated mice
was less pronounced at 3 dps and recovered significantly
faster compared to vehicle controls. These findings are
supported by a more intense glutamine synthetase label-
ing especially of the inner stem processes of Müller glia
in postischemic retinae of animals from the XBD173
group at 3 and 7 dps (7 dps, Fig. 4a; for a better com-
parison, see scans focused to the plane of Müller cell
end feet in retinal flatmounts at 3 dps, the time point of
the most pronounced difference of Glul expression as
indicated by qRT-PCR, Fig. 4e). Accordingly, we specu-
lated that upon XBD173 treatment, some Müller glia
functions were better maintained after transient ischemia.
To follow up on this, we checked for a well-characterized
feature of Müller glia typically affected by their gliotic re-
sponse—their capability to counteract volume changes
when challenged with hyposmotic stress for several mi-
nutes [33]. We found that the mean size of Müller cell
somata of XBD173-treated mice at 7 dps was similar to
that of the control eyes, while there was a trend to lar-
ger Müller cell somata in postischemic retinae of ve-
hicle controls indicative of an altered gliotic response at
7 dps (Fig. 5a). Challenging retinal slices with a solution
of 60% physiological osmolality, gliotic Müller cells
from vehicle control postischemic retinae were not able
to keep their volume constant. In contrast, the volume
of those from the contralateral healthy eyes did not
change (Fig. 5b). No significant Müller cell swelling was
observed in the postischemic retina from XBD173-treated
mice (Fig. 5b), suggesting that neuron-supportive func-
tions of Müller cells are better preserved upon XBD173
treatment.
Recently, we found that progesterone improved the
efficiency of Müller cell volume regulation at nanomolar
concentrations [34]. Considering the possible role of TSPO
in neurosteroid (e.g., progesterone) synthesis [7, 11], it is
tempting to speculate that XBD173 exerts part of its
beneficial effects on Müller cells by enhancing retinal
neurosteroid production. We checked whether retinal
cell types express relevant genes and enzymes (Fig. 6).
Steroidogenic acute regulatory protein (StAR), an
alternative shuttle for cholesterol to the inner mito-
chondrial membrane [35], was not expressed at all (no
transcript or protein was identified via RNA-seq or mass
spectromic analysis, respectively). Thus, TSPO seems to
be the only option to move cholesterol into the mitochon-
dria in retinal cells. Similarly, no expression of Cyp11a1,
typically metabolizing cholesterol to pregnenolone in
mitochondria [36], was found on RNA or protein level in
any of the retinal cell types. However, high levels of
closely related cytochrome p450 family members such
as Cyp20a1, Cyp27a1, Cyp2d11, and Cyp2d26 were
expressed at high levels in Müller glia compared to other
retinal cells (Fig. 6). Similarly, for 3β-hydroxysteroid
dehydrogenase (3β-HSD; gene ID: Hsd3b1), needed for
the generation of progesterone from pregnenolone, no
reads for its transcript or unique peptides indicative for its
expression were identified, while the closely related
Hsd3b7 gene was strongly expressed in Müller cells
(Fig. 6b). Two subtypes of steroid 5α-reductase (5α-R) are
ubiquitously expressed (Srd5a1, Srd5a3; Fig. 6b), while
3α-hydroxysteroid dehydrogenase (3α-HSD, gene ID:
Akr1c4) was not found to be expressed in any retinal cell
type. However, we detected Akr1c13 belonging to the
same gene family as being expressed in Müller glia
(Fig. 6b). These enzymes are involved in further proces-
sing of progesterone to 5α-dihydroprogesterone and
3α,5α-tetrahydroprogesterone with various effects in the
CNS [36]. Surprisingly, the classical progesterone receptor
was not expressed at all, while high protein levels of the
progesterone receptor membrane component 1 (Pgrmc1)
were detected in Müller glia and retinal neurons (Fig. 6b).
This may imply that progesterone effects in the retina
are primarily mediated via Pgrmc1 and not the classical
progesterone receptor.
Fig. 5 Müller cells maintain part of their homeostatic functions in the XBD173-treated postischemic retina. a At 7 dps, Müller cells from wild-type
mice display a slight increase of the mean soma area determined in vital retinal slices on basis of labeling with Mitotracker Orange, which was
not observed in XBD173-treated mice. b Left, the ability of Müller cells to maintain their volume constant was tested by challenging them with a
hypoosmotic solution for 4 min. An efficient Müller cell volume regulation was significantly better preserved in XBD173-treated postischemic
retinae 7 dps, while Müller cells from control eyes did not swell at all. Right, representative images from Müller cell somata loaded with
Mitotracker Orange before and after 4 min of hypoosmotic stress. a, b Bars represent mean values ± SEM from 8 to 20 cells out of 2–3 animals.
**P < 0.01. Scale bars, 10 μm
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XBD173 reduces neurodegeneration in the postischemic
retina
Finally, we characterized the XBD173 effect on neuronal
cell death in our model of transient retinal ischemia
which goes along with considerably thinning of the neu-
rosensory retina (Fig. 7a). We found a significant protec-
tion especially of inner retinal cell types most severely
affected by ischemic damage [6]. Fast degeneration was
seen in cells of the ganglion cell layer which were reduced
to 53.4 ± 10.2% at 7 dps in the vehicle controls but better
survived in mice treated with XBD173 (88.5 ± 5.0%;
Fig. 7b). This protective effect was still present at 14 dps.
In contrast, little difference in cell loss was detected in the
inner nuclear layer (INL) at 7 dps, while at 14 dps, a better
Fig. 6 Expression of genes involved in neurosteroid biosynthesis in different retinal cell populations. a Scheme of neurosteroid synthesis from
cholesterol where one rate-limiting step is its import into mitochondria. b Bar diagrams in (1) reflect the expression of the only cytochrome P450
family genes (Cyp2d11, Cy2d26, Cyp20a1, Cyp27a1) found to be expressed at protein level determined by quantitative LC-MS/MS mass spectrometry
in the distinct retinal cell types. (2–4) Expression of enzymes for further conversion of pregnenolone to progesterone and other neuroactive steroids
was low and only detectable at transcript level by RNA sequencing. (2) The highest expression of 3β-hydroxysteroid dehydrogenase (3β-HSD) type VII
(Hsd3b7) were detected in Müller cells. (3) Two subtypes (Srd5a1, Srd5a3) of steroid 5α-reductase (5α-R) are ubiquitously expressed in all retinal cell
types. (4) Akr1c13 belonging to aldo-keto reductase family 1 gene family (like 3α-hydroxysteroid dehydrogenase (3α-HSD)) is expressed at low levels
and rather specifically in Müller glia. Fpkm, fragments per kilobase million. (5) High protein levels of the progesterone receptor membrane component
1 (PGRMC1) were detected in Müller glia and retinal neurons. Mc, Müller cells; n, neurons; mg, microglia; vc, vascular cells. Hsd3b7, 3β- and
steroid δ-isomerase 7; Srd5a1, steroid 5 alpha-reductase 1; Srd5a3, steroid 5 alpha-reductase 3; Akr1c13, aldo-keto reductase family 1,
member C13
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survival of cells could be shown also in this layer (Fig. 7b).
Given the consistently higher cell counts in the inner re-
tinal layers of XBD173-treated mice, we asked whether
this is also reflected by a better maintenance of synaptic
structures. Analysis of the thickness of the inner and outer
plexiform layers revealed that XBD173 treatment was pro-
tective for neurites. The thickness of both layers was sig-
nificantly better maintained at 14 dps (Fig. 7c). To
quantify ganglion and amacrine cells in the inner retina,
we performed calretinin stainings. Analysis of this subset
Fig. 7 Characterization of the retinal phenotype after transient ischemia with or without XBD173 treatment. a Central retinal slices were stained
with DAPI to visualize the nuclei. b Loss of retinal cells (n = 4–8 animals per group) in the different layers was quantified based on DAPI staining 7
and 14 days post-surgery (dps). c The thickness of the inner and outer plexiform layer (IPL and OPL) was measured in four central retinal slices
from each retina. Bars represent values ± SEM from n = 3–4 of each treatment group. d Calretinin stainings (right) of the central retinal slices were
used to quantify the survival rates (left) of ganglion and displaced amacrine cells (ganglion cell layer, GCL) and amacrine cells in the inner nuclear
layer (INL). Bars represent values ± SEM from n = 3–4 of each treatment group. e Full-field electroretinogram recordings from mice 14 dps show a
reduced responsiveness of retinae from XBD173-treated mice already in the control eyes. The relative reduction in light responsiveness after
transient ischemia was similar in both treatment groups (n = 8 per group). Whiskers indicate the standard deviation. Scale bars, 20 μm
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of cells largely mirrored the findings of the DAPI-based
cell counts confirming the protective effect of XBD173
(Fig. 7d). Note that XBD173 treatment also preserved
the intricate layering of calretinin-positive dendrites
in the IPL. Photoreceptor degeneration occurred to a
similar and comparably low level independent from
the treatment regimen. Survival rates at 14 dps were
still as high as 72.7 ± 9.0% in the vehicle controls and
74.3 ± 10.3% in XBD173-treated mice (Fig. 7b).
Lastly, we tested in electroretinogram (ERG) recordings
whether the higher number of surviving neurons in
treated mice resulted in a better retinal responsiveness to
light stimuli. A- and b-wave amplitudes of control eyes of
XBD173-treated mice were reduced to about 89.9% and
81.3%, respectively, compared to respective amplitudes
measured in untreated animals (Fig. 7e). No differences
between the level of ischemia-induced changes of retinal
light responsiveness could be observed between the
experimental groups (Fig. 7e).
Discussion
For the first time and partially in contrast to previous
studies [21, 22], we showed that TSPO protein expres-
sion was the highest in Müller and vascular cells, but
low in microglia and almost absent in retinal neurons of
the healthy retina (Fig. 2b). Additionally, we found a
strong TSPO expression in RPE (Figs. 1c and 4a). TSPO
in RPE cells was implicated to mediate cholesterol clea-
rance from the subretinal compartment, and its age-re-
lated downregulation may promote progression of
age-related macular degeneration [37]. In view of its high
expression, TSPO function in RPE cells deserves further
studies to elucidate its relevance in retinal disease.
Next, we investigated TSPO expression in postis-
chemic retinae. Like others [22], we found a temporally
defined upregulation of TSPO in microglia (and possibly
macrophages) at 3 dps that declined at 7 and 14 dps
(Fig. 3). With some delay, Müller cells significantly en-
hanced TSPO expression at 7 dps (Fig. 3b), corroborat-
ing the findings of TSPO upregulation in reactive brain
astrocytes [9]. In contrast, no major change in TSPO ex-
pression was found in vascular cells at any time point
post-surgery even though they express TSPO at high
levels apparently relying on its function. Possibly, modu-
lation of TSPO is associated with an active cellular re-
sponse, as it occurs in microglia and Müller cells—those
retinal cell types primarily shaping the retinal immune
response. Considering that TSPO, among other mecha-
nisms, influences the glial energy metabolism [16, 38],
its upregulation in reactive glia may reflect an adaptation
to their higher need for energy to rebalance the
disturbed retinal homeostasis and to mediate an appro-
priate immune response. The energy metabolism of pro-
inflammatory M1 microglia switches from mitochondrial
respiration to primary glycolytic activity and in conse-
quence fosters the generation of detrimental reactive
oxygen species [39, 40]. It could be hypothesized that
enhanced TSPO activity stabilizes the oxidative micro-
glial metabolisms thereby promoting their polarization
towards the protective M2 phenotype. Note that Müller
glia normally generate ATP via anaerobic metabolic
pathways [41], which possibly does not suffice under
pathological conditions so similar beneficial bioenergetic
effects of TSPO stimulation may account for the im-
proved neurosupportive phenotype of Müller glial upon
XBD173 treatment in our retinal ischemia model.
Accordingly, we further characterized in-depth the
glial response pattern. Less microglia accumulated in
XBD173-treated postischemic retinae and the microglial
activation profile implied a trend towards an M2 regen-
erative phenotype (Fig. 3e, f ) confirming recent studies
demonstrating that XBD173 reduces the microglial
neurotoxicity, migration, and proliferation [21, 22]. It
should be emphasized that even if a treatment regimen
was applied as used by others [24], XBD173 effects on
microglia were only moderate and hallmarks of micro-
glial activation (rising cell numbers, upregulation of
TSPO and pro-inflammatory markers, morphological
alterations), even though partially dampened, were still
observed in treated animals (Figs. 2 and 3). Possibly, this
is because transient ischemia disturbs retinal neurons
and glia leading to more severe imbalances of the retinal
homeostasis than in disease models investigated previ-
ously. Consequently, the retinal immune response in-
cluding that of microglia needs to be more powerful
than upon selective photoreceptor loss after light da-
mage [24] or LPS-induced inflammation [22] and thus
partially outruns XBD173 effects.
TSPO in Müller cells has not been investigated to
date. Given that they express highest levels of TSPO
protein compared to all interrogated cell types in the
healthy retina, it was not surprising to find significant
effects of XBD173 on these major retinal macroglia.
XBD173 treatment led to a trend of higher expression
levels of the endogenous ligand DBI in Müller cells
(Fig. 4c) so that beneficial effects of enhanced TSPO
function possibly were reinforced. In addition, DBI was
upregulated in gliotic Müller cells after transient ische-
mia confirming findings from a model of LPS-induced
retinal degeneration [22]. Like in microglia, XBD173 did
not completely abolish Müller cell gliosis as a robust up-
regulation of GFAP, and a temporary downregulation of
glutamine synthetase was found (Fig. 4). However, further
analysis revealed that key features essential to maintain
the neuron-supportive microenvironment were significantly
better preserved in Müller cells upon XBD173 treatment.
Reduction of glutamine synthetase expression was less pro-
nounced and recovered faster (Fig. 4d, e). This Müller
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cell-specific enzyme is key for the glutamate-glutamine
cycle and, hence, for neurotransmitter recycling [42]. Its ac-
tivity fosters glutamate uptake [43] thereby preventing
neurotoxic effects of glutamate [32, 44–46], and recently,
its relevance to maintain the blood-retinal barrier has been
discussed [47]. Additionally, we found that the highly
efficient cell volume regulation of normal Müller cells
stays active in Müller cells of postischemic
XBD173-treated retinae but is lost in gliotic Müller
cells of vehicle controls (Fig. 5). This Müller cell feature
is considered as a prerequisite for their role in stabiliz-
ing the retinal ion and volume homeostasis [1–3] and,
thus, neuronal function. The role of TSPO in the neu-
rosteroidogenesis was intensively studied [7, 11, 13].
Given (i) the high expression levels of TSPO and down-
stream enzymes for neurosteroid synthesis in Müller
glia (Figs. 1 and 6) together with (ii) beneficial effects of
neurosteroids on Müller cell volume regulation [34] as
well as recent reports (iii) demonstrating beneficial
effects including a reduced gliotic activation of Müller
glia upon treatment with the progesterone analogue Nor-
gestrel [48], the effect of XBD173 on Müller cell volume
regulation and gliotic activation pattern might be partially
due to the enhanced neurosteroid synthesis. An aug-
mented retinal allopregnanolone generation upon TSPO
stimulation in retinae was proven recently [23].
Having identified an altered glial response pattern
upon XBD173 treatment that possibly fosters better
neuronal survival, we revisited the question of whether
the TSPO ligand mediates neuroprotection in the postis-
chemic retina. Indeed, we found an improved neuronal
survival in XBD173-treated postischemic retinae. Pro-
nounced effects were observed for inner retinal neurons
and neuronal dendrites (Fig. 7) consistent with our earlier
studies describing protective effects of a better maintained
Müller cell homeostatic function on the survival of these
specific cell types [6]. This strengthens our hypothesis that
cells generating action potentials especially rely on (i) a
tight glial control of glutamate levels and a (ii) well-bal-
anced ion and volume homeostasis. Of note, we found
strong TSPO expression also in the RPE (Fig. 1). However,
since dominant XBD173 effects were observed for neu-
rons of the inner retina (Fig. 7), a contribution of the RPE
is rather unlikely but cannot be completely excluded.
The functional readout via ERG recordings was diffi-
cult to interpret regarding the changes in the postis-
chemic retina as XBD173 dampened a- and b-wave
amplitudes even in healthy control eyes (Fig. 7). A likely
explanation is an enhanced generation of neurosteroids
upon XBD173 treatment (possibly in Müller glia) acting
on GABAA receptors thereby reducing the retinal light
response acting on inhibitory retinal synaptic pathways
[49–51]. Similarly, reduced retinal responses were de-
scribed if individuals were treated with the GABAA
agonist diazepam [52]. In fact, enhanced GABAA recep-
tor activation, e.g., on dendrites of bipolar cells [52, 53],
may contribute to the neuroprotection mediated by
XBD173. However, since the cellular composition of the
postischemic retina changed together with the XBD173 ef-
fect on retinal signaling that possibly differently impacts
on specific retinal subtypes, no conclusion could be drawn
from ERG of the postischemic eyes. Future experiments
should elucidate whether a washout of XBD173 over se-
veral days leads to restoration of normal responses in the
healthy control eye and possibly also detectable diffe-
rences between postischemic eyes from the DMSO and
XBD173 group.
Conclusion
The agonistic TSPO ligand XBD173 significantly reduces
the neuronal cell loss in retinae following transient is-
chemia. Given the predominant expression of TSPO in
micro- and Müller glia in the retina and its absences
from retinal neurons, XBD173 primarily affects glial
cells. The distinct contribution of these two glial entities
to XBD173-mediated neuroprotection needs further
investigation. Our results contribute to the increasing
body of evidence that points at a putative therapeutic
use of TSPO agonists for the treatment of retinal.
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